TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32820223
Drug: Tissue inhibitor
Normalized name: Tissue inhibitor of metalloproteinases 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue inhibitor of MMP (TIMP)-1 expression in AT
Study: 32820223
Drug: Plasminogen activator
Normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasminogen activator inhibitor (PAI)-1 expression in AT
Study: 32820223
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity measured by glucose clamp technique
Study: 32820369
Drug: Pretargeted immuno-PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretargeted immuno-PET using anti-CEA recombinant bispecific monoclonal antibody (BsMAb) TF2 and gallium-68-labelled IMP-288 peptide
Study: 32820369
Drug: BsMAb and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BsMAb and peptide injections
Study: 32820452
Drug: β-glucan, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-glucan, 200 mg/day for 8 weeks
Study: 32820453
Drug: Integrated Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Chinese and Western medicine (ICM) group receiving CM herbal treatment combined with Western medicine (WM) anti-tumor therapy
Study: 32820453
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) group receiving only CM herbal treatment
Study: 32820453
Drug: WM group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: WM group receiving only WM anti-tumor therapy
Study: 32821164
Drug: Apatinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib monotherapy
Study: 32821164
Drug: Apatinib combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib combination therapy
Study: 32821164
Drug: Apatinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (both monotherapy and combination)
Study: 32821287
Drug: Clarithromycin triple
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin triple therapy with add-on NAC
Study: 32821287
Drug: Clarithromycin triple
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin triple therapy alone
Study: 32821422
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of medication (SAM) during hospitalization
Study: 32821712
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (4 g/day) plus statin
Study: 32821737
Drug: New generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New generic rosuvastatin 10 mg daily for 8 weeks
Study: 32821737
Drug: Proprietary rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary rosuvastatin 10 mg daily for 8 weeks
Study: 32824065
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein intake (mean 82.2 ± 21.3 g/d)
Study: 32824392
Drug: Primary tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary tumor resection (PTR) followed by chemotherapy
Study: 32824392
Drug: Upfront chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront chemotherapy alone
Study: 32829467
Drug: Antiviral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral and immunomodulator treatment
Study: 32829481
Drug: Alternative modes
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative modes of exercise therapy (cycling, lower-extremity resistance training, upper-arm ergometry, Nordic walking, combinations of exercise modes)
Study: 32829481
Drug: Alternative modes
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative modes of exercise therapy
Study: 32833107
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) with FI
Study: 32833107
Drug: Non-negative pressure
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-negative pressure wound therapy (non-NPWT) with NFI
Study: 32833717
Drug: Preoperative medications
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative medications
Study: 32833717
Drug: Home medications
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home medications for comorbidities
Study: 32833717
Drug: Intraoperative acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative acetaminophen
Study: 32833717
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia induction
Study: 32838109
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase 50 mg
Study: 32838109
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase 100 mg
Study: 32839491
Drug: AsiDNA 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AsiDNA 600 mg
Study: 32839491
Drug: AsiDNA 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: AsiDNA 900 mg
Study: 32839491
Drug: AsiDNA (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AsiDNA (all doses)
Study: 32840736
Drug: Anti-CD19 Chimeric
Normalized name: allogeneic anti-CD19 chimeric antigen receptor (CAR)-T cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy
Study: 32841335
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine treatment before conception (BC)
Study: 32841335
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine treatment after conception (AC)
Study: 32841541
Drug: Sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib plus doxorubicin (sorafenib 400 mg twice daily and doxorubicin 60 mg/m2)
Study: 32842170
Drug: Basal factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal factor level <0.4 IU/mL
Study: 32843490
Drug: M4112 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: M4112 (100, 200, 400, 600, and 800 mg two times per day orally)
Study: 32843493
Drug: CAR-T targeting
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T targeting carcinoembryonic antigen (CEA) delivered via hepatic artery infusion (HAI) using Pressure-Enabled Drug Delivery (PEDD)
Study: 32843493
Drug: Interleukin-2 systemically
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2 systemically delivered by continuous intravenous infusion
Study: 32844378
Drug: Sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 100 mg every 2 weeks plus 6-month prednisone taper
Study: 32844378
Drug: Sirukumab 50
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 50 mg every 4 weeks plus 6-month prednisone taper
Study: 32844378
Drug: Placebo every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 2 weeks plus 6-month or 12-month prednisone taper
Study: 32845852
Drug: HEpiTracker app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HEpiTracker app for tracking COVID-19 symptoms, daily body temperature, and health score reporting.
Study: 36920756
Drug: Closed-loop system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop system of insulin delivery
Study: 32846062
Drug: Sensor-augmented insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensor-augmented insulin pump (control group)
Study: 32847933
Drug: LY3022855 (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022855 (1.25 mg/kg every 2 weeks)
Study: 32847933
Drug: LY3022855 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022855 (1.0 mg/kg on weeks 1, 2, 4, and 5)
Study: 32847933
Drug: LY3022855 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022855 (100 mg once weekly)
Study: 32847933
Drug: LY3022855 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022855 (100 mg every 2 weeks)
Study: 32847973
Drug: Sorafenib, Bevacizumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib, Bevacizumab, and Paclitaxel (Paclitaxel 80 mg/m2)
Study: 32849667
Drug: Live viral
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live viral vaccines (including measles-mumps-rubella - MMR)
Study: 32849914
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) in combination with bevacizumab/oxaliplatin/fluoropyrimidine regimens (mFOLFOX-6/mOXXEL)
Study: 32850876
Drug: Oral Psoralen
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Psoralen Plus UV-A (PUVA) Photochemotherapy
Study: 32851490
Drug: Oral water
Normalized name: Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral water ingestion
Study: 32856068
Drug: Idelalisib 150
Normalized name: idelalisib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idelalisib 150 mg twice daily
Study: 32856153
Drug: FLER analysis
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLER analysis and visualization using indocyanine green (0.2 mg/kg)
Study: 32857114
Drug: Bimodal Condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimodal Condition (Cochlear Implant + Hearing Aid)
Study: 32857590
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy, details on dosage and duration not specified.
Study: 32858582
Drug: MRI-guided focused
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-guided focused ultrasound (US) treatment
Study: 34550757
Drug: Poziotinib treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poziotinib treatment
Study: 32860424
Drug: Benzodiazepines and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines and Z-drugs (BZD/Z)
Study: 32863016
Drug: Volume expansion
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume expansion with 250 ml of saline 0.9% over 10 min
Study: 32863639
Drug: Protocolized sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized sedative weaning
Study: 32864448
Drug: Modified Lempert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Lempert maneuver (ML)
Study: 32864625
Drug: Alpelisib, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib, a selective inhibitor of PI3Kα
Study: 32865293
Drug: Hetrombopag 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetrombopag 2.5 mg/day
Study: 32865293
Drug: Hetrombopag 5
Normalized name: eltrombopag 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetrombopag 5 mg/day
Study: 32865293
Drug: Hetrombopag 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetrombopag 7.5 mg/day
Study: 32866202
Drug: Tablet App
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet App for the Simplified Gestational Age Score (T-SGAS)
Study: 32867573
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E treatment for 4 weeks
Study: 32867715
Drug: Nivolumab in
Normalized name: nivolumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab in combination with FOLFOXIRI/bevacizumab every 2 weeks for 8 cycles followed by maintenance with bevacizumab plus nivolumab every 2 weeks.
Study: 32867715
Drug: Nivolumab in
Normalized name: nivolumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab in combination with FOLFOXIRI/bevacizumab
Study: 32868037
Drug: Edaravone 30
Normalized name: edaravone 30 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone 30 mg IV infusion over 60 min
Study: 32868346
Drug: Oral flucloxacillin
Normalized name: cloxacillin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral flucloxacillin 500 mg-1 g four times a day
Study: 32870250
Drug: Mavorixafor 400
Normalized name: Mavorixafor
DrugBank: Mavorixafor (DB05501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavorixafor 400 mg once daily
Study: 32873270
Drug: Dose-dense TPF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense TPF (ddTPF) chemotherapy with cisplatin and docetaxel 50 mg/m2 on day 1, leucovorin 250 mg/m2 on day 1, followed by 48-h continuous infusion of 2500 mg/m2 of 5-fluorouracil on day 1 and 2, every 2 weeks for 6 cycles followed by radiotherapy.
Study: 32873343
Drug: Chidamide, decitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chidamide, decitabine, cytarabine, aclarubicin, and G-CSF (CDCAG)
Study: 32874573
Drug: Ixazomib (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib (4.0 mg dose)
Study: 32874839
Drug: Topical atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical atropine 0.125%
Study: 32875289
Drug: onabotulinumtoxinA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: onabotulinumtoxinA treatment
Study: 32876349
Drug: Vedolizumab 300
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 300 mg IV every 4 weeks
Study: 32877254
Drug: Estradiol (E2;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (E2; 4-µg and 10-µg) softgel vaginal insert
Study: 32877573
Drug: UA-lowering drugs
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: UA-lowering drugs
Study: 32878377
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months treatment (defocused communication and behavioural techniques)
Study: 32878566
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy (standard- and low-dose, ≥3× per week)
Study: 32878766
Drug: DKN-01 300
Normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DKN-01 300 mg combined with gemcitabine (1,000 mg/m2) and cisplatin
Study: 32878766
Drug: DKN-01 300
Normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DKN-01 300 mg
Study: 32878766
Drug: DKN-01 600
Normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DKN-01 600 mg
Study: 32879034
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vital sign information with static clinical data
Study: 32879326
Drug: Crolibulin (13-24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crolibulin (13-24 mg/m2)
Study: 32881280
Drug: ctDNA analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: ctDNA analysis with therapy matched to ctDNA alterations (N=33 patients)
Study: 32881886
Drug: L-Arginine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine (100 mg/kg single dose)
Study: 32881886
Drug: L-Arginine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine (100 mg/kg three times daily po X 6 weeks)
Study: 32882399
Drug: Beta-blocker intake
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker intake before exposure to loud noise (∼100 dB)
Study: 32882399
Drug: Beta-blocker intake
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker intake before simulated diving (face immersion in cold water)
Study: 32882958
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health activities incorporated into pediatric well-child visits
Study: 32882958
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard pediatric well-child visits without oral health activities)
Study: 32883871
Drug: CD19-28ζ CAR
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-28ζ CAR T-cell therapy
Study: 32884231
Drug: Topical Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical Latanoprost 0.005%
Study: 32884231
Drug: Topical Timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical Timolol Maleate 0.5%
Study: 32884828
Drug: AbobotulinumtoxinA (aboBoNT-A)
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA (aboBoNT-A) using 2-mL dilution (500 U/2-mL)
Study: 32885188
Drug: BetterBirth intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BetterBirth intervention implementing the WHO Safe Childbirth Checklist; details on dosage and duration not available.
Study: 32885188
Drug: BetterBirth intervention;
Approvals — FDA: no, EMA: no, PMDA: no
Description: BetterBirth intervention; details on dosage and duration not available.
Study: 32885198
Drug: Positive-Minds-Strong Bodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive-Minds-Strong Bodies (PM-SB) intervention consisting of cognitive behavior therapy and exercise training sessions delivered over 6 months.
Study: 32885217
Drug: High scores
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High scores on CFIR organizational characteristics (e.g., organizational readiness, implementation climate, organizational culture, innovation fit)
Study: 32886347
Drug: Imipenem 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem 0.5 g every 6 hours
Study: 32886347
Drug: Imipenem 1
Normalized name: IMIPENEM 1 kg in 1 kg NOT APPLICABLE POWDER [Imipenem]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem 1 g every 6 hours
Study: 32886753
Drug: Rozanolixizumab (15-21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozanolixizumab (15-21 mg/kg cumulative doses, administered as 1 to 5 once-weekly subcutaneous infusions)
Study: 32886753
Drug: Rozanolixizumab (15-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozanolixizumab (15-20 mg/kg single doses)
Study: 32886914
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) levels measured daily in the first 3 days post-aSAH
Study: 32887722
Drug: Ribociclib 600
Normalized name: letrozole 2.5 MG / ribociclib 600 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib 600 mg (3 weeks on, 1 week off) plus Fulvestrant 500 mg
Study: 32887722
Drug: Ribociclib 400
Normalized name: ribociclib 400 MG / letrozole 2.5 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib 400 mg plus Buparlisib 30 mg plus Fulvestrant 500 mg
Study: 32887722
Drug: Ribociclib 400
Normalized name: ribociclib 400 MG / letrozole 2.5 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib 400 mg plus Alpelisib (no RP2D determined)
Study: 32888036
Drug: Serum BMP-7
Normalized name: BMP-7
DrugBank: Eptotermin alfa (DB11631)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Serum BMP-7 with TNF inhibitor (TNFi) use
Study: 32888723
Drug: Long-acting reversible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting reversible contraceptive methods (intrauterine device and contraceptive implant)
Study: 32889146
Drug: AFP ≥7.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFP ≥7.32 ng/mL
Study: 32890324
Drug: Contrast-enhanced ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced ultrasound (CEUS) performed 2 weeks after initial TACE treatment.
Study: 32891132
Drug: Long-term androgen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term androgen treatment
Study: 32891400
Drug: Thrombocytopenia (platelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombocytopenia (platelet count <150 × 10^9/L)
Study: 32891400
Drug: Normal platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal platelet count (≥150 × 10^9/L)
Study: 32891715
Drug: Trifluridine/tipiracil (FTD/TPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil (FTD/TPI) treatment prior to irradiation for 24 hours
Study: 32891715
Drug: Combined in
Normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined in vivo treatment with FTD/TPI and radiation
Study: 32893393
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg dupilumab
Study: 32893393
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg dupilumab
Study: 32893393
Drug: dupilumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: dupilumab (both doses)
Study: 32894185
Drug: CNCT19 CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNCT19 CAR T therapy
Study: 32894672
Drug: Thiol supplements
Normalized name: 1-p-menthene-8-thiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiol supplements
Study: 32894868
Drug: Volatile organic
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volatile organic compounds (VOCs) in bile